Full-Time

Scrum Master

Confirmed live in the last 24 hours

Amgen

Amgen

10,001+ employees

Develops biologic therapies for serious illnesses

No salary listed

Junior, Mid

Hyderabad, Telangana, India

In Person

Category
Project Management
Business & Strategy
Required Skills
Agile
JIRA
SCRUM
Confluence
Development Operations (DevOps)
Requirements
  • Master’s degree and 1 to 3 years of experience in Computer Science, IT or related field experience OR
  • Bachelor’s degree and 3 to 5 years of experience in Computer Science, IT or related field experience OR
  • Diploma and 7 to 9 years of experience in Computer Science, IT or related field experience
  • SAFe Certified Scrum Master (SSM), SAFe Advanced Scrum Master (SASM), or SAFe Release Train Engineer (RTE) certification
  • Hands-on experience with Agile Portfolio Management and Agile Governance
  • Experience as a Scrum Master in Agile and SAFe environments
  • Deep understanding of SAFe principles, Agile Release Trains (ARTs), Lean-Agile frameworks, and Agile coaching
  • Hands-on experience with SAFe Agile ceremonies, PI Planning, Scrum of Scrums, Inspect & Adapt, and Iteration execution
  • Strong knowledge of Agile methodologies (Scrum, Kanban, XP, SAFe) and enterprise Agile transformations
  • Proficiency in Agile project management tools (JIRA, Rally, Azure DevOps, Confluence, Miro)
  • Experience with Lean Portfolio Management (LPM), Lean-Agile metrics, and flow-based work management
  • Ability to coach, mentor, and empower Agile teams, fostering collaboration, servant leadership, and dedication
  • Strong communication and collaborator management skills, ensuring alignment across business and technical teams
  • Understanding of DevOps, CI/CD, Test Automation, and Agile Quality Assurance
  • Proven ability to resolve conflicts, remove blockers, and optimize team performance
Responsibilities
  • Act as a Scrum Master within a Scaled Agile (SAFe) environment, facilitating Agile ceremonies such as PI Planning, Scrum of Scrums, Sprint Planning, Daily Stand-ups, Sprint Reviews, and Inspect & Adapt sessions
  • Guide and support Agile teams, Product Owners, and collaborators, fostering self-organization, cross-team collaboration, and high-performance delivery
  • Coach Agile Release Train (ART) teams on SAFe standard methodologies, Lean-Agile principles, and Agile mentality adoption
  • Facilitate Program Increment (PI) Planning and ART synchronization, ensuring clear dependencies, objectives, and risk mitigation strategies
  • Remove organizational and technical impediments, enabling teams to deliver value faster and with higher quality
  • Promote continuous improvement and relentless execution, guiding teams in identifying and implementing retrospective action items
  • Assist Product Owners and Business Owners in effective backlog management, prioritization, and value-driven decision-making
  • Champion an environment of clarity, psychological safety, and accountability, enabling trust and continuous learning
  • Drive SAFe Lean Portfolio Management practices, ensuring alignment between critical initiatives and Agile execution
  • Enable Agile metrics tracking and reporting, demonstrating KPIs such as Velocity, Flow Efficiency, Lead Time, and Predictability to measure team progress
  • Collaborate with Release Train Engineers (RTEs), Solution Architects, and DevOps teams to optimize delivery pipelines and Agile execution
  • Promote DevOps and CI/CD adoption, fostering a culture of Lean-Agile technical excellence and innovation
  • Stay updated with SAFe and Agile industry trends, continuously improving Agile methodologies, frameworks, and tools
Desired Qualifications
  • Domain experience with Biotech/Pharma industry is a plus
  • Additional certifications in Certified Scrum Master (CSM), Professional Scrum Master (PSM), or SAFe Agilist (SA)
  • Experience in leading SAFe implementations, Agile transformations, and enterprise Agile coaching
  • Knowledge of Value Stream Mapping, Lean Thinking, and OKR-based goal setting

Amgen develops medicines aimed at treating serious illnesses, focusing on biotechnology. The company researches, develops, and sells biologic therapies, which are derived from living organisms, to address conditions like cancer, cardiovascular diseases, and autoimmune disorders. Amgen's products work by utilizing biological processes to create effective treatments for patients. Unlike many competitors, Amgen emphasizes a strong commitment to research and development, reinvesting a large portion of its earnings to discover new therapies. The company's goal is to improve patient care and outcomes by providing effective therapeutic solutions.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of Micromet boosts Amgen's oncology portfolio with BiTE antibody blinatumomab.
  • Institutional investments indicate strong confidence in Amgen's financial health and prospects.
  • Amgen's AI-driven drug discovery investments could accelerate R&D capabilities.

What critics are saying

  • Micromet acquisition may face clinical or regulatory challenges impacting strategic goals.
  • Investor pressure for short-term gains may affect long-term R&D investments.
  • FTC scrutiny on mergers could hinder Amgen's future strategic growth.

What makes Amgen unique

  • Amgen focuses on biologic therapies derived from living organisms.
  • The company has a strong pipeline in oncology, cardiovascular, and autoimmune disorders.
  • Amgen's strategic acquisitions enhance its innovative medicine portfolio.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Amgen
Jun 2nd, 2025
Amgen to Acquire Micromet| Amgen

The acquisition includes blinatumomab, a Bispecific T cell Engager (BiTE) antibody in Phase 2 clinical development for acute lymphoblastic leukemia (ALL). Blinatumomab is also in clinical development for the treatment of non-Hodgkin's lymphoma (NHL), and could have applications in other hematologic malignancies.

MarketBeat
Jan 28th, 2024
Factory Mutual Insurance Co. Makes New Investment in Amgen Inc. (NASDAQ:AMGN)

Factory Mutual Insurance Co. purchased a new position in Amgen Inc. (NASDAQ:AMGN - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 53,500 shares of the medical research company's stock, valued at approxim

The Quantum Insider
Jan 16th, 2024
Honeywell Announces the Closing of $300 Million Equity Investment Round for Quantinuum at $5 Billion Pre-Money Valuation

JPMorgan Chase has one of the world's most highly regarded specialist teams working on quantum technologies within the financial services industry and has been working with Quantinuum and its predecessor companies since 2020.

ETF Daily News
Dec 17th, 2023
Northwest Quadrant Wealth Management LLC Invests $237,000 in Amgen Inc. (NASDAQ:AMGN)

Northwest Quadrant Wealth Management LLC bought a new position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 883 shares of the medical research company’s stock, valued at approximately $237,000. A number of other institutional investors […]

Horizon Therapeutics
Sep 21st, 2023
Rule 2.7 Announcement: Amgen Inc to Acquire Horizon Therapeutics plc | Horizon Therapeutics plc

The Investor Relations website contains information about Horizon Therapeutics plc's business for stockholders, potential investors, and financial analysts.